Covid Vaccine 90% Effective In Phase 3 Trial, Says Pfizer

Views: 479
0 0
Read Time:2 Minute, 36 Second
covid vaccine

Patient prevention was performed seven days after the second two doses and 28 days after the first, according to the start of the study. The covid vaccine is 90% effective in phase 3, Pfizer said
The company says it has reached a milestone in its (representative) vaccination program

A vaccine put together by Pfizer and BioNTech is 90% effective in protecting against the Covid-19 virus by continuing the Phase 3 tests, the company announced Monday.
The announcement was made after coronavirus issues around the world escalated into debt in the European oil and gas market.

According to preliminary data, immunity to patients was obtained seven days after the second two doses and 28 days after the first.

“The first set of results from our Covid-19 phase 3 vaccine training provides the beginning of the immunization potential for Covid-19,” said Albert Bourla, president of the general manager of Pfizer.

“We are one step closer to preparing people around the world with the most needed breakthrough to help end this debilitating health world,” he said.

“We have reached these milestones in our immunization program at a time when the world is in dire need.”

Across the globe, rates of Covid-19 infection have reached high levels, filling critical hospital wards, and increasing the number of deaths.

Based on the information provided, the companies said they expect to provide 50 million vaccines worldwide by 2020 and up to 1.3 billion vaccines by 2021.

The American company Modern Biotechnology is believed to be Chinese state-run factories and a European project led by Oxford University and AstraZeneca.

Two Covid-19 Russian vaccines were registered for us shortly after the medical examination but were not widely accepted outside of Russia.

The phase 3 trial phase – the final step – of the new vaccine, BNT162b2, started in late July and has already registered 43,538 participants, 90 percent of which have received the second vaccine of vaccine candidates since November 8.
Pfizer said it is collecting two months of safety data after the last injection – a requirement from the U.S. Food and Drug Administration – to qualify for emergency clearance, which is waiting three weeks. in November
“We look forward to sharing additional information about the effectiveness and safety built by thousands of participants in the coming weeks,” Bourla said.

Covid Vaccine and Many other candidates

The chemical called messenger RNA or mRNA is a new way of protecting against viruses.

Unlike traditional vaccines, which are useful in educating the body to recognize and break down proteins produced by pathogens, mRNA secretes the patient’s immune system to build proteins itself.

Proteins are harmless, but they only stimulate the immune response.

The study will also evaluate the potential vaccine candidate for COVID-19 in those previously affected by SARS-CoV-2, as well as the vaccine against severe infections. of COVID-19 diseases.

Pfizer and BioNTech aim to provide data from a full 3 part research for the scientific publication of peer review.

Since mid-October, the World Health Organization (WHO) has announced 42 “vaccines” in clinical trials, from 11 to mid-June.

Average Rating

5 Star
4 Star
3 Star
2 Star
1 Star

Leave a Comment